School of Chemical Engineering, School of Chemistry and Life Science, Advanced Institute of Materials Science, Changchun University of Technology, 2055 Yanan Street, Changchun, Jilin 130012, PR China.
School of Chemical Engineering, School of Chemistry and Life Science, Advanced Institute of Materials Science, Changchun University of Technology, 2055 Yanan Street, Changchun, Jilin 130012, PR China.
J Colloid Interface Sci. 2019 Feb 1;535:84-91. doi: 10.1016/j.jcis.2018.09.095. Epub 2018 Sep 27.
Carrier-free nanodrugs named BCNPs were prepared by the coassembly of 2,5-bis(4-(diethylamino)benzylidene)cyclopentanone (BDBC) and curcumin (CCM) in the absence of surfactants. The as-synthesized BCNPs possess high dispersity and stability in aqueous media, along with favorable photostability and good biocompatibility. Comparing with their counterparts BDBC and CCM, BCNPs exhibit higher singlet oxygen yield and better two-photon photodynamic therapy (PDT) efficacy. Moreover, BCNPs display dramatically enhanced ability for inhibiting the growth of HeLa cells, which benefits from the synergistic treatment of BDBC and CCM under the irradiation of 450/808 nm. This work highlights the potential of using simple coassembly strategy to codelivery of multiple drugs in one single formulation for cancer therapy.
无载体纳米药物 BCNPs 通过 2,5-双(4-(二乙氨基)亚苄基)环戊酮 (BDBC) 和姜黄素 (CCM) 在无表面活性剂存在的情况下共组装制备而成。所合成的 BCNPs 在水介质中具有高分散性和稳定性,同时具有良好的光稳定性和良好的生物相容性。与它们的对应物 BDBC 和 CCM 相比,BCNPs 表现出更高的单线态氧产率和更好的双光子光动力治疗 (PDT) 效果。此外,BCNPs 显示出显著增强的抑制 HeLa 细胞生长的能力,这得益于在 450/808nm 照射下 BDBC 和 CCM 的协同治疗。这项工作突出了使用简单的共组装策略将多种药物共递送到单一制剂中用于癌症治疗的潜力。